Novartis AG (FRA:NOT) FFO


FRA:NOT Novartis AG FRA:NOT
83 GF Score
Price €131.52
GF Value €109.77
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novartis AG FFO?

FFO (Funds from operations) only applies to REITs.

FRA:NOT
83GF Score
Novartis AG FRA:NOT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novartis AG (FRA:NOT) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €131.52 is trading 19.8% above its estimated GF Value™ of €109.77. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOT:

  • FFO:
  • GF Value™: €109.77 vs. price of €131.52 (19.8% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the FRA:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score

Get the complete analysis for FRA:NOT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€131.52
Price
€109.77
GF Value